Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp

Bullboard Posts

Comment by BigShoes13on Dec 03, 2013 4:46pm

70 Views

Post# 21965756

RE:RE:Someone knows if they put a deadline on each LOI ?

Well who knows how long it will take but the length between the first LOI's and any deals is extraordinarily long in this case. The Cincinnati Children's Hospital LOI was signed in May. VitamFerro in June. Biogalenys in July.

Yet no deals. Seven months is an extremely long period of time.

It should make us wonder what is happening. But most are simply blind to any questions as they just see posts of $1.00, etc.

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading